BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2008-11-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 111
- Registration Number
- NCT00798252
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00796991
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Solid Tumors
- Conditions
- Advanced Solid TumorsMetastatic Solid Tumors
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT00793897
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00792558
- Locations
- 🇸🇬
Local Institution, Singapore, Singapore
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 40
- Registration Number
- NCT00788333
- Locations
- 🇬🇧
Local Institution, Newcastle Upon Tyne, Tyne And Wear, United Kingdom
Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT00779428
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00780000
Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2013-08-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 371
- Registration Number
- NCT00778622
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib
- First Posted Date
- 2008-10-22
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 130
- Registration Number
- NCT00777036
- Locations
- 🇨🇦
Local Institution - 0078, Edmonton, Alberta, Canada
🇺🇸Local Institution - 0028, Seattle, Washington, United States
🇺🇸Seattle Children'S, Seattle, Washington, United States
Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2015-11-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00773344
- Locations
- 🇺🇸
Premiere Oncology Of Arizona, Scottsdale, Arizona, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States